Comparison
Abacavir Hypersensitivity C5768819 vs 3m Syndrome 3 C3280146
Clinical comparison between Abacavir Hypersensitivity and 3M Syndrome 3 for differential diagnosis and treatment planning.
Abacavir Hypersensitivity C5768819
A potentially serious immune reaction to the HIV drug abacavir. Genetic testing is required before starting treatment to identify those at risk of this reaction.
3m Syndrome 3 C3280146
A genetic condition causing intrauterine growth restriction and postnatal short stature with distinctive facial features. Treatment focuses on growth monitoring and supportive measures.
6 comparison axes
Onset
Abacavir Hypersensitivity C5768819
Variable
3m Syndrome 3 C3280146
0-0
Onset patterns differ
Severity
Abacavir Hypersensitivity C5768819
severe
3m Syndrome 3 C3280146
moderate
Different severity levels
Chronic
Abacavir Hypersensitivity C5768819
Acute
3m Syndrome 3 C3280146
Chronic
Differing course
Communicable
Abacavir Hypersensitivity C5768819
No
3m Syndrome 3 C3280146
No
Different transmission
Body System
Abacavir Hypersensitivity C5768819
immunologic
3m Syndrome 3 C3280146
musculoskeletal
Same/different system
Category
Abacavir Hypersensitivity C5768819
immunologic
3m Syndrome 3 C3280146
genetic
Different category
Bottom line
abacavir-hypersensitivity-C5768819 and 3m-syndrome-3-C3280146 differ in severity, chronicity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | Abacavir Hypersensitivity C5768819 | 3m Syndrome 3 C3280146 | Discriminating power |
|---|---|---|---|
| Onset | Variable, generally after abacavir exposure. | Congenital, with prenatal growth restriction. | High |
| Principal features | Immune drug reaction; exact symptoms are not fixed here. | Short stature and distinctive facial features. | Moderate |
| Course | Acute and potentially severe. | Chronic and generally moderate. | High |
When to favor each condition
Choose Abacavir Hypersensitivity C5768819 when
Illness after starting abacavir
Recent exposure supports evaluation for hypersensitivity.
High
HLA-B*5701 risk identified
This indicates risk, not an active reaction.
Moderate
Planning abacavir therapy
Required genetic risk testing precedes treatment.
High
Choose 3m Syndrome 3 C3280146 when
Prenatal or birth growth restriction
Congenital onset fits 3M syndrome 3.
High
Persistent short stature and facial features
These source features warrant genetic assessment.
Moderate
Confirmed syndrome-related genetics
Molecular confirmation separates it from drug reaction.
High
How key tests differ
| Test | Abacavir Hypersensitivity C5768819 | 3m Syndrome 3 C3280146 | Interpretation |
|---|---|---|---|
| HLA-B*5701 testing | Assesses abacavir reaction risk. | Not relevant to the syndrome. | A risk test, not proof of active hypersensitivity. |
| Growth assessment | No characteristic growth pattern established. | Intrauterine and postnatal growth impairment. | Serial measurements support syndrome evaluation. |
| Diagnostic genetic testing | Pharmacogenetic testing addresses drug risk. | Syndrome testing is considered when suspected. | Choose tests according to exposure or congenital phenotype. |
Prognosis comparison
Abacavir Hypersensitivity C5768819
- Outcome
- Potentially serious, depending on recognition and management.
- Factors
- Exposure timing and clinician-directed care.
3m Syndrome 3 C3280146
- Outcome
- Chronic course with variable growth needs.
- Factors
- Growth pattern, features, and supportive care.
Time frame: Hours to days versus lifelong follow-up.
No shared prognosis is established.
Complications comparison
| Complication | Presentation |
|---|---|
| Severe reaction | Potentially serious and needs urgent clinician review. Not a feature of the syndrome. Do not restart abacavir after suspected reaction unless a specialist advises. |
| Growth impairment | Not established by the source. Short stature may persist. Supportive monitoring is central; outcomes vary. |
| Diagnostic confusion | May resemble infection or another drug effect. May resemble other growth syndromes. Neither finding excludes the other without clinical context. |
Patient education highlights
- HighUrgent review
Possible abacavir hypersensitivity needs prompt care; do not change HIV medicines independently.
- MediumGenetic counseling
3M syndrome 3 is genetic; counseling explains testing and inheritance limits.
- LowSeparate conditions
A drug reaction neither causes nor rules out this congenital syndrome.